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Abstract
Katrina McClatchey is a 2004 graduate of the University of Oklahoma College of Law and an
associate at the Oklahoma City law firm of Dunlap, Codding & Rogers, P.C. Below, Ms.
McClatchey discusses the function and jurisdiction of the European Patent Convention (EPC)
treaty and the European Patent Office (EPO) that the treaty established. The EPO issues a single
patent that is enforceable in as many countries as the applicant wishes to designate. This makes
obtaining patent protection in many European countries not only possible but extremely efficient
as well. While the requirements for a European patent are similar to the requirements for a
United States patent, Ms. McClatchey highlights some important distinctions of which
biotechnologists should be aware.
Edited by Steve Ruby
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I.

Introduction

Biotechnological research and product development relating to living organisms, such as
microorganisms as well as plants and animals, have become expanding industries. In order to
exploit the commercial potential of new innovations, biotechnologists can seek protection under
a patent, much like what has be done in the past for non-living inventions.
Generally, a patent grants an inventor the exclusive right to make commercial use of an
invention for a limited time. This adds value to the invention because, under the protection of a
patent, an inventor can stop others from making, using or selling the invention without the
inventor’s authorization. However, patents are legal titles which are territorial in nature. This
means that a patent only offers protection within the territorial boundaries of the country that
grants the inventor the patent. In other words, there is no such thing as a “worldwide” patent.
Therefore, an inventor must file for and obtain a patent in each country where protection is
desired.
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Various countries around the world, each with a unique culture, have responded
differently to the notion of patenting “life.” However, patent systems in Europe have undergone
recent developments which are more readily adaptive to technological changes and industrial
advancements. These developments have overcome some of the prior hostility toward the
patenting of living organisms and offer encouraging prospects for a biotechnology market. Thus,
as a general overview, this eBrief will discuss one major avenue in Europe which is open to
biotechnologists seeking protection of their work relating to microorganisms, plants and animals:
the European patent.
II.

Background of the European Patent Convention and the European Patent Office
When protection is sought in a number of countries, an inventor can be faced with

multiple legal systems, patent authorities, procedural and substantive requirements, time
limitations, costs, language barriers, etc. To help ameliorate such burdens faced by an applicant,
and thus facilitate the patent process in Europe, some European countries have joined together
under a treaty known as the European Patent Convention (EPC) 1 , under which the European
Patent Office (EPO) 2 was created. For EPC member countries, the EPO acts as a central
searching and examining authority for patent applications, and grants European patents for patent
applications which qualify under certain standard rules. The EPC sets forth the framework for

1

The European Patent Convention, also known as the Convention on the Grant of European Patents, was signed in
Munich on Oct. 5, 1973 and entered into force in Oct. 7, 1977. Convention on the Grant of European Patents, Oct.
5, 1973, 13 I.L.M. 268, http://www.european-patent-office.org/legal/epc/e/ma1.html#CVN [hereinafter EPC].
Presently, contracting member states to the EPC include Austria, Belgium, Bulgaria, Cyprus, Czech Republic,
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Liechtenstein, Luxembourg, Monaco,
Netherlands, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.
Some non-member countries that have been extended protection of the EPO through agreements include Albania,
Latvia, Lithuania, and the former Yugoslav Republic of Macedonia. Mewburn Ellis, LLP, What Is a European
Patent?, at http://www.mewburn.com/pateutxt.htm (last visited Oct. 26, 2004).
2
The European Patent Office (EPO) is the executive arm of the European Patent Organisation, an intergovernmental
body set up under the EPC. The EPO received the first European patent applications on June 1, 1978. European
Patent Organisation, Facts and Figures (2002), at http://www.european-patentoffice.org/epo/facts_figures/facts2001/pdf/facts_figures_01.pdf.

2

2 OKLA. J. L. & TECH. 25 (2004)
www.okjolt.org
how the EPO is to operate by determining what constitutes a patentable invention and the
process of obtaining and maintaining a European patent.
Through the EPO, an applicant can file and prosecute a single patent application in one
language (English, French, or German). 3 If granted by the EPO, a European patent results in a
national patent in as many member countries as the applicant wishes to designate. 4 While the
applicant may be required to file additional translations for the designated countries, the cost of
these translations is not expended by the applicant until after being assured that the EPO will
grant a European patent on the application. 5 As such, the EPO application process allows the
applicant to avoid the time and expense of filing and prosecuting separate patent applications in
various languages before the national patent offices of the member countries. 6
Once a patent is granted and formalities such as translations and payment of fees have
been complied with, the effect of a European patent in any country in which it is in force is the
same as that of a national patent issued in that country. 7 Questions of infringement for a granted
European patent are left to the national law in each individual member country in which
protection is sought. 8

In interpreting the scope of the European patent, the EPC instructs

member countries that “[t]he extent of protection conferred by a European patent or a European
patent application shall be determined by the terms of the claims. Nevertheless, the description

3

EPC, supra note 1, art. 14(1).
Id. arts. 3, 79(1). The designation of a contracting country is subject to the payment of a “designation fee”. Id. art.
79(2). In addition to designation fees, an inventor may also wish to consider other factors such as related
expenditures (translation costs for example), where protection is desired (where the invention would be marketed
and/or manufactured for example), or where competitor markets or manufacturers are located; and the feasibility of
markets, (in countries with high regulatory and approval requirements for example).
5
EPC, supra note 1, art. 65(1).
6
Taking into account the fees paid in the course of the grant procedure, representation fees for one qualified
representative, and the cost of conducting the procedure in only one language, the cost of obtaining a European
patent is approximately the same as cost of obtaining three to four national patents. The Guide for Applicants, Part
1, ch. A, § IV, point 22, http://www.european-patent-office.org/ap_gd/index.htm (last visited Feb. 25, 2004).
7
EPC, supra note 1, arts. 2(2), 64(1).
8
Id. art. 64(3).
4
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and drawings shall be used to interpret the claims.” 9 Other requirements the EPC imposes on its
member countries provide that:
•

•
•

the European patent has a term of 20 years from the filing date 10 (with the
possibility of extension in cases of national emergency 11 or to compensate
for marketing delay caused by the need for obtaining approval from a
governmental entity), 12
process patents confer protection on products directly obtained by the
process, 13 and
the collection of compensation for use of the invention after the
application is published, but before the patent is granted, must be provided
for in circumstances where liability under national law for infringement of
a national patent would exist 14 (provided that, if required by the member
country, a translation of the claims pending in the application were filed in
the national patent office of the country where such collection is
pursued). 15
III.

EPC Requirements for European Patent

For a biotechnologist to obtain the protection of a European patent for a living-invention,
certain substantive requirements set forth by the EPC must be met. For an invention to be
patentable, it must be “new,” involve an “inventive step,” and be susceptible to “industrial
application.” 16 These requirements are similar to (but not entirely the same as) the Unites States
patentability requirements of “novelty,” 17 “non-obviousness” 18 and “usefulness.” 19

Summarily,

novelty requires that the invention not form a part of the “state of the art,” 20 i.e. the invention
must not be a part of the information or knowledge made available to the public by means of

9

Id. art. 69(1).
Id. art. 63(1).
11
Id. art. 63(2)(a).
12
Id. art. 63(2)(b).
13
Id. art. 64(2).
14
Id. art. 67(2).
15
Id. art. 67(3).
16
Id. art. 52(1).
17
35 U.S.C. § 102 (2000).
18
Id. § 103.
19
Id. § 101.
20
EPC, supra note 1, art. 54(1).
10
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written or oral description, use, or any other way, before the filing date of the patent application
disclosing the invention. 21 An invention involves an inventive step “if having regard to the state
of the art, it is not obvious to a person skilled in the art.” 22 An invention is susceptible of
industrial application “if it can be made or used in any kind of industry, including agriculture.” 23
Furthermore, an invention must also be within the patentable statutory subject matter, i.e.
it must be the type of subject matter to which protection will be afforded. This area is where
most biotechnology inventors face the most burdensome hurdles when trying to obtain patent
protection around the world, as some countries may not recognize living organisms as
“patentable subject matter.” With regard to the EPC, there are not details of what qualifies as a
patentable “invention,” but there is a non-exhaustive list of things that “shall not be regarded as
inventions.” 24 In general, the items on this list are either abstract and/or non-technical (in
contrast to being concrete and of technical character). 25 More particularly, the EPC provides that
the following shall not be regarded as “inventions:”
•
•
•
•

“discoveries, scientific theories and mathematical methods;” 26
“aesthetic creations;” 27
“schemes, rules and methods for performing mental acts, playing games or
doing business, and programs for computers;” 28 and
“presentations of information.” 29

21

Id. art. 54(2).
Id. art. 56.
23
Id. art. 57.
24
Guidelines for Examination, Part C, ch. IV, § 2.1, at http://www.european-patentoffice.org/legal/gui_lines/index.htm (last visited Feb. 25, 2004).
25
Id.
26
EPC, supra note 1, art. 52(2)(a).
27
Id. art. 52(2)(b). For example, paintings and sculptures with no technical features would not be patentable.
Guidelines for Examination, supra note 24, § 2.3.4.
28
EPC, supra note 1, art. 52(2)(c). For example, a scheme for learning a language, a method of solving crossword
puzzles, a game as an abstract entity defined by its rules, or a scheme for organizing a commercial operation as such
would not be patentable. Guidelines for Examination, supra note 24, § 2.3.5.
22
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However, these prohibitions are applicable only to the extent that a European patent
application or European patent relates to such subject-matter or activities “as such.” 30 Thus, if
the application relates to technical subject-matter beyond the abstract or non-technical subjectmatter, such that the content of the claimed subject-matter as a whole has a technical character,
then there may be a patentable invention. 31
Most applicable to the biotechnology community is the exclusion from patentability of
“discoveries, scientific theories and mathematical methods.” 32 Finding a new property of a
known material or article, or finding a previously unrecognized substance occurring in nature, is
a mere “discovery” which does not have technical effect and, therefore, is unpatentable as such. 33
However, if that new property is put to practical use, or if the substance found in nature can be
shown to produce a technical effect, then it constitutes an invention that may be patentable. 34
For example, if a substance occurring in nature (e.g. a microorganism) is found to have an
antibiotic effect, then such use and the substance itself may be patentable as aspects of the
invention. 35 Similarly, a gene discovered to exist in nature may be patentable if a technical effect
is revealed (e.g. its use in making a certain polypeptide or in gene therapy). 36 Further, biological
material 37 that is isolated from its natural environment or produced by means of a technical
process can also be patentable, even if it previously occurred in nature. 38

29

EPC, supra note 1, art. 52(2)(d). For example, a representation of information, such as spoken words or a book,
which lacks technical features and which is defined solely by the content of the information it contains is not
patentable. Guidelines for Examination, supra note 24, § 2.3.7.
30
EPC, supra note 1, art. 52(3).
31
Guidelines for Examination, supra note 24, § 2.2.
32
See Guidelines for Examination, supra note 24, Part C, ch. IV.
33
Id. § 2.3.1.
34
Id.
35
Id.
36
Id.
37
“Biological material” is defined as “any material which contains genetic information and is capable of
reproducing itself or being reproduced in a biological system.” Implementing Regulations to the Convention on the
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“Scientific theories” are more generalized forms of discoveries and, as such, are
evaluated under the same principles. 39

For example, while the physical theory of

semiconductivity would not be patentable as such, new semiconductor devices, or processes for
manufacturing the semiconductor devices, may be patentable. 40 “Mathematical methods” are
considered purely abstract and thus are not patentable as such. 41 For example, a shortcut method
of division would not be patentable. 42 However, a calculating machine constructed to operate
according to this method may be patentable. 43
Additionally, “methods of treatment of the human or animal body by surgery or therapy
and diagnostic methods practiced on the human or animal body” are not regarded as inventions
that are susceptible of industrial application.44 However, this provision does not apply to
products, in particular substances or compositions, for use in any of these methods. 45
IV.

Unpatentable Exceptions to the EPC

Furthermore, and of particular importance to a biotechnology inventor of a living
organism, the EPC also provides “exceptions to patentability,” wherein European patents will not
be granted for inventions that are “contrary to ‘ordre public’ or morality,” 46 or for “plant or
animal varieties or essentially biological processes for the production of plants or animals.” 47
Irrespective of the connotation of these prohibitions on patentable subject matter, living matter

Grant of European Patents, Dec. 13, 2001, Rule 23b(3), at http://www.european-patentoffice.org/legal/epc/e/ma2.html#REG (last visited Feb. 20, 2004) [hereinafter Implementing Regulations].
38
Id. Rule 23c(a).
39
Guidelines for Examination, supra note 24, § 2.3.2.
40
Id.
41
Id. § 2.3.3
42
Id.
43
Id.
44
EPC, supra note 1, art. 52(4).
45
Id.
46
Id. art. 53(a).
47
Id. art. 53(b).
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does not appear, in a practical sense, to be entirely excluded from patentability under the EPC.
As a general matter, the EPO case law appears more adaptive to technological progress by
adopting a general attitude that “the purpose of a law (ratio legis) is not merely a matter of the
actual intention of the legislators at the time when the law was adopted but also of their
presumed intention in the light of changes in circumstances which have taken place since then.” 48
Moreover, EPO case law and regulations implementing the EPC tend to interpret the EPC
exceptions to patentability narrowly, thus maintaining the European patent as a real possibility
for living inventions.
Summarily, under the “ordre public or morality” exception, “[i]nventions, the
exploitation of which is not in conformity with the conventionally accepted standards of conduct
pertaining to the culture inherent in European society and civilization are to be excluded from
patentability as being contrary to morality.” 49 However, exploitation is not contrary to ordre
public or morality merely because it is prohibited by law or regulation in some or all of the
member states. 50 Further, a survey or opinion poll showing that a particular group of people (or
even a majority of the population) in some or all of the member states oppose the granting of a
patent for a specified subject-matter, cannot serve as a sufficient criterion for establishing that
the subject-matter is contrary to ordre public or morality. 51
More specifically, the concept of “ordre public” covers the protection of public security,
the physical integrity of individuals as part of society, and the environment. 52

Thus, if

exploitation of an invention would “seriously prejudice the environment,” it may be contrary to

48

HARVARD/Onco-mouse (T19/90), [1990] E.P.O.R. 501, 510.
PLANT GENETIC SYSTEMS/Glutamine synthetase inhibitors (T356/93), [1995] E.P.O.R. 357, 366.
50
EPC, supra note 1, art. 53(a).
51
PLANT GENETIC SYSTEMS/Glutamine synthetase inhibitors, supra note 49, at 369.
52
Id. at 366.
49
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ordre public. 53 However, more than a “possibility” of undesired or destructive effects resulting
in damage to the environment (such as for example the transfer of herbicide resistant genes to
weeds) may be required to show a sufficient threat to the environment. 54 Furthermore, seeds and
plants, per se, do not constitute exceptions to patentability merely because they represent living
matter or on the ground that plant genetic resources should remain the common heritage of
mankind. 55
Exploitation resulting in the suffering of animals, or other possible risks to the
environment posed by the introduction of genetically manipulated animals, may implicate the
“ordre public or morality” exception. 56

However, such considerations should be balanced

carefully against the invention’s usefulness to mankind when deciding whether or not the
exception will bar patenting of the invention.57 For example, processes for modifying the genetic
identity of animals which are likely to cause them suffering without any substantial medical
benefit to man or animal are specifically unpatentable, along with animals resulting from such
processes. 58
Other specific biotechnological inventions which remain unpatentable as being contrary
to ordre public or morality pertain to the integrity of humans. 59 These include processes for
cloning human beings, 60 processes for modifying the germ line genetic identity of human
beings, 61 and uses of human embryos for industrial or commercial purposes. 62

53

Id.
Id. at 372.
55
Id. at 368.
56
HARVARD/Onco-mouse, supra note 48, at 513.
57
Id.
58
Implementing Regulations, supra note 37, Rule 23d(d).
59
Id.
60
Id. Rule 23d(a).
61
Id. Rule 23d(b).
62
Id. Rule 23d(c).
54
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Under the exception to “plant and animal varieties,” “[n]o general exclusion of inventions
in the sphere of animate nature can be inferred.” 63

The exception has been literally, and

narrowly, interpreted to mean that biotechnological inventions which concern plants or animals
can be patentable, provided that the patent application is not technically confined to a single
plant or animal variety. 64 With regard to plants, 65 a claim which does not individually claim or
identify specific plant varieties is not excluded from patentability, even if it embraces or may
embrace one or more plant varieties. 66 Also, a claim to a process for the production of a plant
variety is not excluded from patentability merely because the resulting product constitutes a plant
variety. 67

With regard to animals, 68 the exception to patentablity for animal varieties has been

interpreted to apply only to certain categories of animals, but not to animals in general.69
Therefore, if the subject-matter of the claimed invention is not limited to the categories defined
by the terms used in the EPC, i.e. “animal variety” (in English), “race animale” (in French), and
“Tierart” (in German), then the exception to patentablity does not apply. 70 , 71

63

CIBA-GEIGY/Propagating material (T49/83), [1979-85] E.P.O.R. C758, 759.
Implementing Regulations, supra note 37, Rule 23c(b).
65
For a more comprehensive discussion on the application of the “plant varieties” exception, see Katrina
McClatchey, The Effect of the “Onco-Mouse” Decisions on the Exception to Patentability for “Animal Varieties”
Under the European Patent Convention, 2 OKLA. J.L. & TECH. 22 (2004).
66
NOVARTIS/Transgenic plant (G01/98), [2000] E.P.O.R. 303, 319.
67
Id.
68
For a more comprehensive discussion on the application of the “animal varieties” exception, see Katrina
McClatchey, The Impact of Novartis on the European Patent Convention’s Exception to Patentability for "Plant
Varieties,” 2 OKLA. J.L. & TECH. 21 (2004).
69
HARVARD/Onco-mouse, supra note 48, at 511.
70
Id.
71
After being remitted the task of interpreting the concept of “animal varieties” and its counterparts, and applying it
to claims for “rodents” and non-human “mammals”, the Examining Division of the EPO found that “rodents or even
mammals constitute a taxonomic classification unit much higher than species ('Tierart'). An 'animal variety' or 'race
animal' is a sub-unit of a species and therefore of even lower ranking than a species. Accordingly, the subjectmatter of the claims to animals per se is considered not to be covered by the above three terms of Article 53(b)
EPC.” HARVARD/Onco-mouse, [1991] E.P.O.R. 525, 526.
64
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“Essentially biological processes for the production of plants or animals” are also
unpatentable under the EPC. 72 However, this provision does not apply to “microbiological
processes” or the “products thereof.” 73 Whether or not a process is “essentially biological”
depends on the essence of the invention, considering the amount of human intervention and its
impact on the result achieved. 74 However, human intervention alone is not sufficient to make the
process not “essentially biological.” 75
A process for the production of plants or animals is essentially biological if it consists
entirely of “natural phenomena,” such as crossing or selection. 76 For example, a method of
crossing, inter-breeding, or selectively breeding animals (e.g., horses) by merely selecting for
breeding and bringing together those animals having certain characteristics would be essentially
biological and therefore unpatentable. 77 On the other hand, a process of treating a plant or
animal to improve its properties or yield, or to promote or suppress its growth (e.g., a method of
pruning a tree) would not be considered “essentially biological” because, although a biological
process is involved, the essence of the invention is technical. 78 The same could apply to a
method of treating a plant characterized by the application of a growth-stimulating substance or
radiation, or to the treatment of soil by technical means to suppress or promote the growth of
plants. 79
Biotechnological inventions involving a microbiological or other technical process, or a
product obtained by means of such a process (other than a plant or animal variety) are

72

EPC, supra note 1, art. 53(b).
Id.
74
LUBRIZOL/Hybrid plants (T320/87), [1990] E.P.O.R. 173, 178.
75
Id.
76
Implementing Regulations, supra note 37, Rule 23b(5).
77
Guidelines for Examination, supra note 24, § 3.4.2.
78
Id.
79
Id.
73
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patentable. 80

A "microbiological process" is “any process involving or performed upon or

resulting in microbiological material.” 81 The term “microbiological” qualifies activities that
include processes which make direct use of microorganisms. 82
Microbiological activities include fermentation, biotransformation, genetic engineering,
chemical engineering, fusion techniques, recombinant techniques, or any other activity in which
an integrated use is made of biochemical and microbiological techniques in order to exploit the
capacities of microbes and cultured cells. 83

Microorganisms include generally unicellular

organisms with dimensions beneath the limits of vision which can be propagated and
manipulated in a laboratory, such as bacteria, yeast plasmids, viruses, fungi, algae, protozoa and
human, animal and plant cells.84 Thus, "microbiological processes" include processes in which
microorganisms (or their parts) are used to make or to modify products, or in which new
microorganisms are developed for specific uses. 85

“Products of microbiological processes”

include products which were made or modified by microorganisms as well as new
microorganisms as such. 86
V.

Conclusion

In summary, case law, rules, and provisions under the EPC make the EPO, and the
European patent, an open avenue for biotechnologists and living inventions. Furthermore, the
EPO offers a practical and resource-efficient system in which inventors can obtain protection in
multiple member countries by filing and prosecuting a single patent application in one language.

80

Implementing Regulations, supra note 37, Rule 23c(c).
Id. Rule 23b(6).
82
PLANT GENETIC SYSTEMS/Glutamine synthetase inhibitors, supra note 49, at 378.
83
Id.
84
Id. at 377-78.
85
Id. at 378.
86
Id.
81
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Such developments encourage technological progress and investment in Europe. As a result, the
European patent offers many benefits and commercial opportunities to the biotechnology
community, including those involved in research and product development relating to
microorganisms, plants, and animals.
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